Abhenil Mittal
@abhenilmittal
Followers
1K
Following
2K
Statuses
1K
MedOnc, Asst Prof at NOSMU,Breast, GU and Thoracic Cancers, Health service researcher, Coffee and sports lover, 🇮🇳 to 🇨🇦, Opinions my own
Greater Sudbury / Grand Sudbur
Joined June 2011
U of T fellowship graduation ceremony! Humbled at the opportunity to have trained at such a great institution! Excited for the road ahead! @UofT_DoM @UofT @pmcancercentre
23
3
83
RT @DrMarkLythgoe: Very interesting letter from @oncology_bg (and co)about use of below sub-optimal control arms to adulate clinical outcom…
0
7
0
@nihardesai89 @JCO_ASCO Yeah unfortunately it is. Its like a control arm of len-dex for transplant eligible myeloma while testing a quad or BiTE, maybe even worse!
0
0
1
0
3
0
RT @dr_yakupergun: An excellent letter regarding the design of the ARANOTE trial. I sincerely congratulate the authors. I had also submitt…
0
9
0
RT @pash22: Putting up with Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial via @abhenilmittal &…
0
11
0
0
0
0
RT @ErikaHamilton9: It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt. 4% ⬆️ recurrence in pts w/ n…
0
24
0
RT @gusviani: Do all early-stage breast cancer patients need axillary surgery? The INSEMA trial challenges this long-standing practice, sho…
0
70
0
@5_utr I am glad this is reporting out. I am a medonc and I find the approach of 5 years of Endocrine therapy instead of 5 days of radiation not reasonable. ET provides small benefits and risk of radiation is too amplified
0
1
9
Excellent summary by @oncology_bg on our recent paper on #SurrogateEndPoints in @eClinicalMed @TheLancet.
Surrogate endpoints in oncology trials remain controversial. Our latest article answers 15 common questions, addressing pitfalls and the way forward. Learn why OS and QoL should be the gold standards. #ClinicalTrials @oncology_bg @TheLancet
1
2
5
0
0
0
0
0
0
@nihardesai7 Would probably still be an oncologist- I think I love it too much. But travel the world, all countries atleast once, if possible
1
0
16
@dr_yakupergun This is quite bad. Enrolled in lot of non- north american countries with limited ARAT access, and will be used to apply for approval in the US. Sad that this enrolled in Canada too. @oncology_bg
1
0
9
RT @oncology_bg: What questions can you think of regarding surrogate endpoints in oncology? We try to answer them all in this review. This…
0
31
0
Thank you @oncology_bg and @Claudia_Editor for the opportunity. Hopefully this paper would be a good resource for anyone interested in reading about surrogate end points in oncology! @drbrookewilson @csoncol @HSN_Sudbury @thenosm
SIMULTANEOUS PUBLICATION ALERT!🚨 As I mentioned in my talk, a comprehensive review answering most frequently asked questions on surrogate endpoints in oncology has been simultaneously published in @eClinicalMed today with our @myESMO MCBS session. OPEN ACCESS. Thanks to all my coauthors for putting a lot of effort into this and to @Claudia_Editor for inviting this review and getting it published simultaneously with our MCBS session.
1
3
20
@MSRandhawa192 @PsychoMaan Btw, work weeks in most north american countries in residency are about 70-80 hours on average (that is what we often compare to). Expectation of 48 hour work weeks in residency is stupid. No one should undergo harassment/torture but working is not equal to torture!
1
0
1